睾酮治疗对性腺功能减退男性良性前列腺增生的影响
基于2011—2020年MarketScan数据库882,570例性腺功能减退男性的队列分析显示,睾酮治疗前2.5年与良性前列腺增生(BPH)诊断风险无显著差异(HR 1,95%CI 0.98-1.01,P=.66),2.5年后接受睾酮治疗者BPH诊断风险升高32%(HR 1.32,95%CI 1.28-1.36,P<.001);已患BPH者接受睾酮治疗与干预需求无显著差异(HR 0.95,95%CI 0.89-1,P=.08)。
要点
- 性腺功能减退男性睾酮治疗前2.5年BPH诊断风险与未治疗者无显著差异(HR 1,95%CI 0.98-1.01,P=.66)。
- 2.5年后接受睾酮治疗者BPH诊断风险较未治疗者升高32%(HR 1.32,95%CI 1.28-1.36,P<.001)。
- 已患BPH的性腺功能减退男性接受睾酮治疗与未治疗者在前列腺干预需求上无显著差异(HR 0.95,95%CI 0.89-1,P=.08)。
核心结论
- 长期来看,睾酮治疗增加性腺功能减退男性接受BPH诊断的风险。
- 性腺功能减退合并BPH的男性接受睾酮治疗未改变干预需求。
研究设计与样本
- 使用2011—2020年International Business Machines Corporation MarketScan数据库识别18岁以上性腺功能减退男性并确定是否接受睾酮治疗。
- 采用国际疾病分类第9和第10版、当前操作术语、医疗保健通用操作编码系统操作码及国家药品代码(NDC)进行诊断、干预和药物编码。
- 运行Cox比例风险模型评估睾酮治疗对BPH诊断和干预的影响,模型校正年龄、地区、人口密度和合并症,近6个月内睾酮治疗作为时变协变量。
主要发现
- 总队列882,570例性腺功能减退男性中,157,185例(17.8%)被诊断为BPH。
- 性腺功能减退诊断后前2.5年,接受睾酮治疗者与未接受者前列腺增生诊断无显著差异(HR 1,95%CI 0.98-1.01,P=.66)。
- 2.5年后,接受睾酮治疗男性BPH诊断风险较未接受者高32%(HR 1.32,95%CI 1.28-1.36,P<.001)。
- 合并BPH的性腺功能减退男性中,接受睾酮治疗者与未接受者干预需求无显著差异(HR 0.95,95%CI 0.89-1,P=.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the impact of testosterone therapy (TT) on the incidence of benign prostatic hyperplasia (BPH) in a large cohort of hypogonadal males and to evaluate the relationship between TT in hypogonadal males and prostatic interventions. METHODS: We used the 2011-2020 International Business Machines Corporation MarketScan database to identify hypogonadal males above 18 years old and determine if they received TT. International Classification of Diseases, 9th and 10th Revisions, Current Procedural Terminology, Healthcare Common Procedure Coding System Procedure Codes, and National Drug Code (NDC) codes were used for diagnoses, interventions, and medications. We ran Cox proportional hazard models to determine the effect of TT on receiving a diagnosis of BPH and interventions. Models were adjusted for age, region, population density, and comorbidities, with TT within the last 6 months considered a time-varying covariate. RESULTS: In our total cohort of 882,570 hypogonadal males, 157,185 (17.8%) were diagnosed with BPH. For the first 2.5 years after hypogonadism diagnosis, there was no significant difference in the diagnosis of prostatic hyperplasia between patients on TT and those who were not (HR:1, 95%CI:0.98-1.01, P = .66). However, from 2.5 years onward, males who were on TT had a 32% higher risk of receiving a diagnosis of BPH (HR:1.32, 95%CI:1.28-1.36, P <.001). Hypogonadal males with BPH who received TT showed no significant difference in interventions compared to those who did not receive testosterone (HR:0.95, 95%CI:0.89-1, P = .08). CONCLUSION: In the long term, TT increased the risk of receiving a diagnosis of BPH in hypogonadal males. TT in hypogonadal males with BPH did not change the need for interventions.
引用
- Fendereski K, Horns JJ, Dehghanbanadaki H, et al. The Impact of Testosterone Therapy on Benign Prostatic Hyperplasia in Hypogonadal Males. Urology. 2024. PMID: 39550043. doi:10.1016/j.urology.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。